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High-grade serous ovarian cancer (HGSOC) is the most 
common subtype of ovarian cancer (1). This cancer 
is a heterogeneous disease associated with few shared 
genetic mutations (BRCA1, BRCA2, p53) (2) and with 
widely accepted origination from the fallopian tube 
epithelium (FTE). Eighty percent to 90% of HGSOCs, 
after malignant transformation, express the paired box 
transcription factor 8 (PAX8) (3). This transcriptional factor 
is normally expressed in the FTE but not in the healthy 
ovarian surface epithelium (OSE) (4). Several studies have 
recently reported PAX8 pivotal function in the migration, 
invasion and tumorigenic ability of ovarian cancer cells. 
Loss PAX8 in ovarian cancer cell lines decreases in vitro 
and in vivo tumor phenotype and promotes apoptosis (4-6). 
Hence, there is a growing interest to evaluate PAX8 not 
only as a diagnostic biomarker but also as a potential 
therapeutic target for HGSOC. However, the key pathways 
that allow PAX8 to regulate cellular processes in FTE and 
in HGSOC is still poorly understood.
In this scenario, Hardy at al. recently reported the first 
proteomic study of PAX8 regulated pathways in human 
ovarian cancer cell models and in normal OSE cell models 
after PAX8 alterations (7). They used as model cells the 
OVCAR8RFP human ovarian cancer cell line and the 
normal murine ovarian surface epithelium (MOSE) cells. 
This choice was based on the findings of their previous 
work that evaluated the role of PAX8 in cells derived from 
the two progenitor sites of HGSOC: OSE and FTE (5). 
The work demonstrated that PAX8 deletion in the adult 
FTE, where it is normally expressed, did not have evident 
phenotypic effects and gene expression alterations. On the 
contrary, in OSE cells the forced PAX8 expression led to 
a malignant phenotype (5). Hence, the proteomic analysis 
was performed on OVCAR8RFP versus OVCAR8RFP cells 
after PAX8 deletion (OVCAR8RFPPAX8−/−) and on MOSE 
versus MOSE cells stably expressing PAX8 (MOSE-PAX8) 
by using isobaric labelling strategy (SILAC and iTRAQ) (7). 
The Gene Ontology (GO) analysis of the differentially 
expressed proteins in OVCAR8RFP and MOSE cells pointed 
out the enrichment of pathways involved in cytoskeletal 
structure, cadherin binding and ubiquitin protein ligase 
binding, but only 28 proteins were regulated by PAX8 in 
both cell lines. In line with their previous study, N-Cadherin 
(CDH2) a key mediator of cell adhesion, was upregulated in 
both MOSE and OVCAR8 cells. Conversely, Protein kinase 
Cα (PKCα) was increased only in OVCAR8 cells while the 
actin filaments ACTN1 and ACTN4 were upregulated 
only in MOSE cells. The authors explained that these 
differences could be due to the marked reprogramming 
of the PAX8 cistrome across FTE and HGSOC cell 
lines as demonstrated by Elias et al. (8). The proteomic 
data obtained in MOSE-PAX8 cells were confirmed by 
RNA-sequencing analysis. Among the 4,257 transcripts 
modified by PAX8, 187 were found to be also affected 
in the proteomic analysis. Gene set enrichment analysis 
(GSEA) of these datasets pointed out the KEGG adherens 
junction pathways as differentially regulated by PAX8. 
GSEA analysis identified ACTN1 and ACTN4 as drivers 
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of adherens junction in MOSE-PAX8 cells. These findings 
were supported by functional assays. The proteomic data 
were also validated in HGSOC cells by in vitro migration 
assay. The results confirmed that PAX8 increased migration 
and metastasis in HGSOC cells. Based on these findings, 
the authors decided to validate the influence of PAX8 on 
cytoskeleton analysing the migratory and invasive ability of 
serous tumor cells derived from the OSE, FTE and human 
HGSOC. They knocked down PAX8 in spontaneously 
transformed murine OSE (STOSE) tumor cells and in 
murine oviductal epithelium (MOE PTENshRNA /KRASG12V) 
cells. They demonstrated that PAX8 increased migration 
and metastasis regardless of cell of origin. Despite this, the 
PAX8 downstream transcriptional targets are dependent 
on tumor’s cell of origin. The authors proved that PAX8 
increased migration in HGSOC cell lines by upregulation 
of PCKα but not in MOSE cells. Conversely, in MOSE 
cells PAX8 regulated ACTN1 and ACTN4 to promote 
adherens junctions but not in OVCAR8. The authors 
stated that these unique downstream targets of PAX8 in 
OVCAR8 and MOSE cell lines could be due to lineage 
and tumor specific DNA binding sites. This hypothesis 
is supported by previous work of Elias et al. (8). Through 
whole transcriptome shotgun sequencing (RNA-Seq) after 
PAX8 knockdown and ChIP-Seq in fallopian tube secretory 
epithelial cells (FTSECs) and HGSOCs, they pointed out 
that ovarian cancer cells displayed marked reprogramming 
of the PAX8 cistrome (8). Based on these data, Hardy et al. 
hypothesized the acquisition of a DNA binding near PCKα 
in OVCAR8 cells during the malignant transformation. 
Despite the lineage and tumor specificity of PAX8 
binding sites, the ability of PAX8 to regulate the migration 
is conserved across the cell types examined. For this reason, 
Hardy et al. suggested PAX8 as valuable drug target to 
reduce the metastasis and increase survival of HGSOC 
patients regardless of cell of origins. The authors proposed 
the use of drug thiostrepton, a thiazole antibiotic to 
target PAX8. This natural product inhibits prokaryotic 
translational through the binding of 70S ribosome and 
it is known to suppress breast cancer cell migration, 
metastasis, and transformation, through downregulation 
of the forkhead transcription factor FOXM1 expression 
(9,10). Moreover, FOXM1 is an oncogene activated in 
over 80% of HGSOC (11). Hardy et al. demonstrated that 
thiostrepton did not affect the PAX8 transcription but 
destabilised the PAX8 protein level both in OVCAR8 and 
in MOSE-PAX8 cells. This PAX8 protein reduction was 
not affected by FOXM1 expression or proteasome activity. 
The authors attempted to confirm in vivo the ability of 
thiostrepton to target PAX8 and reduce tumor progression 
and aggressiveness. They used six-week-old female athymic 
nude mice inoculated i.p. with OVCAR8 cells and after a 
week treated with thiostrepton. The administration of un-
encapsulated drug to reduce the tumor was unsuccessful due 
to toxic effects and solubility issues. Conversely, the treatment 
with thiostrepton encapsulated in sterically stabilised micelles 
(SSM) composed of PEGylated phospholipid, DSPE-
PEG2000 led to a significantly reduction of tumor burden. 
Moreover, immunoblotting analysis on tumor tissue pointed 
out the ability of thiostrepton-SSM to reduce both FOXM1 
and PAX8 levels. The decreased PCKα levels associated 
with PAX8 reduction by thiostrepton-SSM treatment 
in vivo was confirmed through immunohistochemistry assays.
The innovative feature of the work, presented by Hardy 
et al., is the use of “omic” approach (proteomics and 
transcriptomics) to examine the role of PAX8 in peritoneal 
colonization of HGSOC. 
Previously published papers dealt with transcriptomic 
analysis of ovarian cancer cells with PAX8 alterations, an 
approach that provides information only about the effects 
on gene expression. The “omic” data have allowed pointing 
out the unifying role of PAX8 as a master regulator of 
migration regardless of cell of origin but with unique 
transcriptional targets depending on the cell’s site of origin. 
They proposed PCKα as one of the unique differentially 
regulated proteins in HGSOC cells while ACTN1 and 
ACTN4 as distinctive of MOSE cells. The strength of the 
work depends on being able to validate the results through 
both in vitro and in vivo functional assays. The results led 
the authors to propose PAX8 as an effective drug target 
to treat HGSOC derived from both the OSE and FTE. 
Promising results were obtained on murine models treated 
with the micelle encapsulated drug thiostrepton.
Some critical technical aspects of the study are still 
lacking. The proteomic analysis revealed 28 proteins 
differentially expressed in both HGSOC and MOSE cells. 
However, the authors decided not to include all these 
proteins in the subsequent validation analysis. Indeed, they 
confirmed only CDH5, a protein found to be affected by 
PAX8 in their previous work. The same choice was applied 
on the proteins exclusively differentially expressed in 
HGSOC and MOSE cells. They investigated the effects of 
PAX8 on PCKα in HGSOC cells or ACTN1 and ACTN4 
in MOSE cells. The analysis of the entire “omic” dataset is 
needed to completely elucidate the regulated pathways by 
PAX8 in ovarian cancer. 
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Another critical aspect of the work is the use of a single 
human ovarian cancer cell line (OVCAR8). Genomic 
differences between ovarian cancer cell lines and tissue 
samples have been pointed out in several studies (12). Hence, 
further studies on other HGSOC cell line models as well 
as on cells derived from patients are needed to confirm the 
proposed role of PAX8 as a master regulator of migration 
in ovarian cancer. New findings will allow undoubtedly 
proposing PAX8 as drug target for HGSOC therapy.
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